Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Definium Therapeutics, Inc. - Common Shares
(NQ:
DFTX
)
35.97
+0.35 (+0.97%)
Delayed Quote
Updated: 12:08 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Definium Therapeutics, Inc. - Common Shares
< Previous
1
2
3
Next >
Which stocks are moving on Monday?
↗
June 22, 2026
Via
Chartmill
Monday's session: gap up and gap down stocks
↗
June 22, 2026
Via
Chartmill
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
June 22, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
June 21, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics (NASDAQ:DFTX) Misses EPS but Pipeline Progress Steals the Spotlight
↗
May 07, 2026
Via
Chartmill
Definium Therapeutics Announces New Employee Inducement Grants
June 15, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
June 01, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
↗
May 22, 2026
Definium Therapeutics (NASDAQ:DFTX) Chief Financial Officer Brandi Roberts said the company is preparing for several key clinical and regulatory milestones for DT-120, including anticipated Phase III...
Via
MarketBeat
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 21, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing
↗
May 18, 2026
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Via
The Motley Fool
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish
↗
May 18, 2026
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
May 12, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
May 11, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium (DFTX) Q1 2026 Earnings Transcript
↗
May 07, 2026
Definium (DFTX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
May 07, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
These 3 Psychedelic Stocks Activated After Trump's Executive Order
↗
April 27, 2026
Via
MarketBeat
Topics
Government
Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day
April 22, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
April 20, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
↗
April 20, 2026
Trump is easing approval for psychedelic treatments for mental disorders.
Via
The Motley Fool
Topics
Government
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
April 18, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
April 09, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
March 31, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics Announces New Employee Inducement Grants
March 30, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026
March 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
↗
March 18, 2026
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.
Via
The Motley Fool
Topics
Regulatory Compliance
Definium Therapeutics Announces New Employee Inducement Grants
March 09, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium (DFTX) Q4 2025 Earnings Call Transcript
↗
February 27, 2026
Definium (DFTX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
February 26, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2026
From
Definium Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
